NCT06193538View on ClinicalTrials.gov

The Safety and Effectiveness of NV-A01 in Glioma Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 14, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

July 31, 2025

Conditions
Advanced Glioblastoma Patients
Interventions
DRUG

Recombinant NV-A01 adenovirus injection

Patients with advanced glioblastoma were intratumoral injected with NV-A01. Or the NV-A01 was injected after tumor resection.

Trial Locations (1)

Unknown

RECRUITING

Wannan medical college hospital, Wuhu

All Listed Sponsors
lead

First Affiliated Hospital of Wannan Medical College

OTHER